FDA Issues Warning on Overdoses from Compounded Semaglutide Injections

Patients are experiencing severe health complications due to dosing errors with off-brand versions of popular weight-loss drugs.

The FDA reports a rise in adverse events from compounded semaglutide, including nausea, vomiting, and pancreatitis.
Confusion over dosing measurements and unfamiliarity with self-injection are major contributors to these errors.
Some patients have taken doses up to 20 times higher than recommended, leading to hospitalizations.
Compounded versions of semaglutide lack FDA approval and vary in concentration, increasing the risk of overdose.
Patients are advised to consult healthcare providers for proper dosing instructions and to use approved medications when available.